The results of human clinical trials completed at Russia's Sechenov University were reported to have proven the effectiveness of its vaccine candidate, according to Elena Smolyarchuk, the head and chief researcher at the university's Center for Clinical Research on Medications, Russia's TASS news agency reported Monday.
"The research has been completed and it proved that the vaccine is safe. The volunteers [of the clinical trials] will be discharged on 15 July and 20 July," Smolyarchuk told TASS.
The participants of the trials will remain under medical supervision on an out-patient basis after they are discharged, Smolyarchuk noted.
Alexander Gintsburg, head of Russia's Gamalei Institute of Epidemiology and Microbiology where the vaccine was developed, hopes the vaccine will "enter civil circulation" on August 12 to 14 and that private companies will begin mass production by September, he told TASS.
Clinical trials on two formulations of the vaccine candidate were launched last month at Sechenov University, with 18 people vaccinated on June 18, followed by a second group of 20 people vaccinated on June 23, TASS reported.
The potential vaccine has reportedly been developed by the same government labs that produced an effective vaccine for the Ebola virus as well as MERS virus, The Washington Post reported.